Safety-Related Labeling Changes
Contraindicated in patients with severe renal impairment or ESRD (CrCl less than 30 mL per minute) who are concomitantly taking potent CYP3A inhibitors or inducers.
Trade Name
Celsentri
Updated Section
4.3 Contraindications
Month
Mar,2024